 Genetic Technologies Limited ASX: GTG; NASDAQ: GENE the Company, a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct offering of 722,502 American Depositary Shares ADSs, each representing six hundred 600 of the Companys ordinary shares, at a purchase price of 2.00 per ADS for gross proceeds of approximately 1.44 million. The Company intends to use the net proceeds from this offering to support the introduction and distribution of its new products in the United States, for general product research and development, including the development of polygenic risk tests with TGen in the United States, for implementation of its consumer initiated testing platform and preparation for Covid-19 testing as well as for working capital. 